Downstream Processing Featured Articles

  1. Saint-Gobain's New C-Flex® ULTRA Pump Tubing For Biopharmaceutical Applications Outperforms The Competition 6/28/2012

    Saint-Gobain Performance Plastics has expanded its line of thermoplastic elastomer (TPE) tubing with the addition of new C-Flex® ULTRA pump tubing, a product designed specifically to perform in demanding biopharmaceutical applications such as pumping, single-use assemblies, process filling and sampling.

  2. Research Breakthrough Selectively Represses The Immune System 11/19/2012

    In a mouse model of multiple sclerosis (MS), researchers funded by the National Institutes of Health have developed innovative technology to selectively inhibit the part of the immune system responsible for attacking myelin -- the insulating material that encases nerve fibers and facilitates electrical communication between brain cells.

  3. Is The Single-Use Standardization Debate Slowing Down Adoption? 3/16/2015

    Without single-use standardization, the customization required to build a single-use facility may prevent a full-scale adoption of single-use technology. So how do we move forward? Maybe, by taking a look back.

  4. Abbott To Collaborate With Astellas In CMV Vaccine Trial 9/7/2012

    Abbott announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovirus (CMV) reactivation in transplant patients.

  5. Damania Lab Discovers Gene That Suppresses Herpesviruses 2/14/2013

    In a paper published by Cell Host and Microbe on Feb. 13, a research team led by Blossom Damania, PhD, of the Department of Microbiology and Immunology and member of the UNC Lineberger Comprehensive Cancer Center, found that suppressing the TLK enzyme causes the activation of the lytic cycle of both EBV and KSHV. During this active phase, these viruses begin to spread and replicate, and become vulnerable to anti-viral treatments.

  6. Advanced BioScience Laboratories Awards Avid Bioservices HIV Vaccine Development And Manufacturing Contract 9/27/2012

    Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc., today announced that it has been chosen by Advanced BioScience Laboratories, Inc. (ABL) to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection.

  7. Kimberly-Clark Professional Launches Innovative RightCycle Program To Recycle Single-Use Cleanroom And Laboratory Gloves And Garments 4/25/2013

    To provide cleanrooms and laboratories with effective solutions to mitigate waste and enhance Corporate Social Responsibility (CSR) and sustainability efforts, Kimberly-Clark Professional has introduced RightCycle – the first large-scale recycling effort for nontraditional cleanroom waste. 

  8. High-Flow Sterile Connectors For Single-Use Applications

    Over the past decade, two developments have increased demand for high fl ow-rate connectors: Size advances in single-use bioreactors up to 2000L and the  implementation of single-use downstream.

  9. Population Genetics Validates GenomePooling For Cancer 7/31/2012

    Population Genetics Technologies Ltd., creator of innovative methods for genetic analyses and biomarker discovery, has successfully completed a pilot study to prove that its GenomePooling method is sensitive and accurate enough to detect even small percentages of gene variants within cancer tissue. This validates the method’s suitability for use in IntReALL 2010, the world’s largest genetic analysis of acute lymphoblastic leukaemia (ALL) relapse cases. ALL is the most common childhood malignant disease.

  10. MorphoSys Receives First Patent On Novel Antibody Platform Ylanthia In The US 2/8/2013

    MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and Trademark Office (USPTO) has granted the first patent covering the Company's latest antibody platform Ylanthia, which became commercially available for existing and new partners in 2012.